Cellular Origins and Fresenius Kabi announced completion of the first integration phase of their collaboration to automate cell and gene therapy (CGT) manufacturing. The teams integrated Fresenius Kabi’s Cue R Cell Processing System into Cellular Origins’ Constellation R robotic platform and validated complex human T‑cell workflows, reducing manual touchpoints and variability in early studies. Company executives framed the milestone as a step toward fully automated, clinically relevant CGT manufacturing that can lower costs and improve scalability. The integration targets a well‑recognized bottleneck in CGT commercialization—labor‑intensive, variable operations—potentially enabling more consistent supply chains for cell therapies.